THE TAPE

Axsome Therapeutics, Inc

$137.01▼ −3.30%
Last close
Relative strength
10RS
of 99, against every stock▼ -16 on the month
Falling back
Unconfirmed
−45.8%
six months against Pharmaceutical Preparations
52-week range
−47.3%
from the high
$123.00$260.19
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth REALProof PENDING
Quarter to Sep 30, revenue +52% on a year ago
Why it is on no screen

AXSM is off the screens on 3 checks.

A base has formed21.0 weeks, from 123.00 to 260.19.
Long enough to count21.0 weeks against 3 needed.
Shallow enough52.7% deep against 35% allowed.
Close to its pivot-47.3% from the pivot; listed down to -20%.
Relative strengthRS 10 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance

No price has been tested three times in the last 120 sessions: it has not spent long enough in one range to form a level.

The read

Axsome Therapeutics, Inc is not on any of the screens right now. Its relative strength rating is 10, and it sits in Pharmaceutical Preparations.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against its industry
-16.5%
Three months against its industry
-26.6%
Six months against its industry
-45.8%

Read against an equal-weighted index of Pharmaceutical Preparations, which is +10.9% against the S&P 500 over six months Partly aligned.

Peers
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 3.0% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$865.3M
+51.9% year on year
Operating margin
-17.5%
Net margin
-18.2%
Free cash flow
$-82.6M
-1.2% of market cap
Price to sales
8.29×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 2
Key takeaway
Real growth, but execution and cash generation are not yet proven.
Revenue
$259.7M
+18.9% QoQ · +51.9% YoY
Gross margin
—
Net income
−$12.9M
Loss
Free cash flow
−$9.7M
Burning · 33q runway

What the numbers say

  • Good: Revenue +51.9% year over year, +18.9% on the quarter
  • Weak: Net loss $13M, narrower than $51M last quarter
  • Weak: Burning cash: operating cash flow -$9M, free cash flow -$10M, better than -$33M last quarter · 32 quarters of cash at this burn
  • Weak: Growth externally funded: capex $197K against operating cash flow -$9M
  • Good: Net cash $126M · cash $314M
Revenue by quarter
Free cash flow
Net income
shares +4.8% in a year · net cash $125.8M

What is not obvious

  • Weak: Stock compensation $26M added back against negative operating cash flow

The desk’s own read

Flagged as drifting down since the report

Final read
Growth: REAL · Economic proof: PENDING
Key question: Can the growth turn into durable profit and cash after its costs and financing?
The next test is operating profit: net loss $13M, narrower than $51M last quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 3 of 46 tracked funds at the end of Q3 2026.

Last quarter: 2 bought new, 1 trimmed.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
GappedTape · 2026-11-12
+5.9%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-11
+5.2%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-06
-5.3%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Reported resultsFiling · 2026-11-03
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
GappedTape · 2026-11-03
-5.8%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ down on earningsTape · 2026-11-03
-5.8% on earnings 2026-11-02
No measurable effect: stocks behave like random ones over the next three sessions (665 cases over 44 nights).
Unusual volumeTape · 2026-11-03
4.7 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
Closed below its 20- and 50-day on heavy volumeTape · 2026-10-31
below 20d & 50d on 2.5x volume at 144.43
No measurable effect: stocks behave like random ones over the next three sessions (1,780 cases over 60 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
14
$48,917,248 total

Sold: Jacobson Mark L., TABUTEAU HERRIOT, JEFFS ROGER, Mahony Susan, Coleman Mark, Pizzie Nick.

Not counted above: 10 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-09-03 Jacobson Mark L. · Chief Operating Officeroption exercise10,000$129,500
2026-09-03 Jacobson Mark L. · Chief Operating Officersell10,000$2,086,500
2026-08-06 TABUTEAU HERRIOT · Chief Executive Officer, Director, 10% owneroption exercise4,660$23,067
2026-08-06 TABUTEAU HERRIOT · Chief Executive Officer, Director, 10% ownersell4,660$997,007
2026-08-05 TABUTEAU HERRIOT · Chief Executive Officer, Director, 10% owneroption exercise45,004$222,770
2026-08-05 TABUTEAU HERRIOT · Chief Executive Officer, Director, 10% ownersell45,004$9,541,298
2026-07-01 TABUTEAU HERRIOT · Chief Executive Officer, Director, 10% owneroption exercise49,666$245,847
2026-07-01 TABUTEAU HERRIOT · Chief Executive Officer, Director, 10% ownersell49,666$11,932,257

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What analysts expect
Strong buy3
Buy18
Hold1
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Axsome Therapeutics, Inc (AXSM) — The Tape